Ambu A S Ord (AMBFF) Q3 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Ambu A/s Class B.

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:05.078 Hello, everyone, and a warm welcome to this earnings call where we 00:00:05.078 -- 00:00:07.942 will present our Q3 24-25 00:00:07.942 -- 00:00:09.344 financial 00:00:09.344 -- 00:00:10.766 results. 00:00:10.766 -- 00:00:13.490 I'm Britt Mielbjørnsen. I'm the CEO of Ambu. 00:00:13.490 -- 00:00:18.698 And with me today, I have Henrik Skagbender, our Chief Financial Officer. 00:00:18.698 -- 00:00:22.964 We'll give a short presentation on the business results, the financial results, and then 00:00:22.964 -- 00:00:26.727 we will open up for questions. 00:00:27.655 -- 00:00:33.484 If we move to the next slide, the usual disclaimer, and then moving into 00:00:33.484 -- 00:00:38.693 the highlights of this quarter or the first nine months of our financial 00:00:38.693 -- 00:00:42.359 year ending September 30th. 00:00:42.359 -- 00:00:47.708 We have seen solid growth momentum continuing and looking at the nine-month 00:00:47.708 -- 00:00:53.694 period that we have had, we have a total growth of 14.3%. 00:00:54.098 -- 00:00:59.287 Again, with our fiscal year ending September 30th, that also means 00:00:59.287 -- 00:01:01.651 that we are comfortable 00:01:01.651 -- 00:01:06.599 with today's results to also lift the lower end of our guidance. 00:01:06.599 -- 00:01:12.489 So the guidance on our organic revenue growth for the full year is now 12-14% 00:01:12.489 -- 00:01:16.051 instead of previous 11-14%. 00:01:17.234 -- 00:01:22.340 On the new launches, we continue to have good progress both on the pulmonology 00:01:22.340 -- 00:01:28.046 and urology side. I'll come back to that, but exciting advancements 00:01:28.046 -- 00:01:33.953 in the quarter of the portfolio. In terms of sustainability, which also remains important 00:01:33.953 -- 00:01:3...